Sai Life Sciences — an Indian CRDMO choosing market share over margin

The Pulse

Sai Life Sciences is a Hyderabad-based contract research, development and manufacturing organisation — a CRDMO, the pharma industry’s outsourced lab-and-factory — that just delivered the year its long capacity build was supposed to pay for: FY26 revenue up 29% to ₹2,192 crores, EBITDA up 56%, profit more than doubled to ₹349 crores, and the 28–30% margin target hit a year or two ahead of its own schedule. The structural story is large global pharma consolidating its drug pipeline work into India, and Sai — which now works with 19 of the world’s top 25 pharma companies — is one of the main beneficiaries. Management’s response is the defining fact of the moment: rather than harvest the margin, they are doubling capex to ₹1,100–1,300 crores in FY27 to grab share while the China+1 window is open. The stock, at 73 times earnings and within 1% of its 52-week high, is priced as if this all works.

The Business

Sai runs the full conveyor belt of drug-making for hire. At the front end, its discovery business (CRO, about 35% of revenue) rents out chemists and biologists to design and test drug candidates. At the back end, its development-and-manufacturing business (CDMO, about 65%) takes molecules that survive clinical trials and makes them at commercial scale. The company is almost entirely an export machine — 98.7% of FY25 revenue came from outside India, earned off a capital base that sits 94% in India. That gap between where the costs are and where the customers are is the basic arbitrage.

What makes it more than a commodity chemistry shop is the integration. A client’s molecule can enter at discovery and stay through commercial manufacturing — Sai claims to be approved by all three of a client’s internal departments (discovery, development, commercial), which founder-MD Krishna Kanumuri calls being “the only company really stitched all these together.” The funnel shows it working: 34 molecules in commercial manufacturing (up from 30 a quarter earlier), 11 in Phase III or pre-registration, and roughly 155 in earlier development feeding the pipe. Revenue from top-25 pharma clients has gone from 28% of the total in FY22 to 49% in FY26 — which is also why Sai kept growing through a biotech funding winter that hurt discovery-only peers. Concentration is managed deliberately: the top customer is ~12% of revenue, and management prefers many $5–10 million molecules over chasing blockbusters, because — as they candidly admit — a CDMO gets “blindsided” by customer destocking and no contract guarantees volumes.

Ownership is unusual. The founding Kanumuri family holds only ~35%, and since the December 2024 IPO the register has been institutionalised at remarkable speed — public holding collapsed from 41% to under 13% in five quarters as domestic funds (now 31.5%, the largest holder class) and foreign funds absorbed the pre-IPO exits.

How Management Thinks

Kanumuri and CFO Siva Chittor run one of the more interesting acts on Indian earnings calls: aggressive in deed, conservative in word. The only numbers they will commit to are 15–20% revenue growth over three to five years and a 28–30% EBITDA margin — guidance they held flat even while printing 43% nine-month growth and a 34% quarterly margin. They say it plainly: internal targets “are generally higher than the street targets.”

The strategic doctrine is explicit growth-over-margin. Kanumuri’s argument: every Indian CRDMO is subscale against Chinese rivals who run 25–30% margins at far larger size, so “if you over-optimize for margin, you potentially will be leaving market share… we have to be careful what we wish for.” Hence the capex doubling, the zero dividend, and a tolerance for asset turns dipping before recovering to their stated 1.2–1.4x. Capex is framed as “science-led, not reactor-led” — built against customer conversations and pipeline visibility, not speculation — and the FY26 record mildly supports the discipline claim: they spent ₹633 crores against a ₹700 crore budget.

Their candour is genuinely above average where it costs them nothing competitively: “apples-to-apples, China is still significantly ahead of India — that’s just an honest fact”; the animal-health facility is a pivot from a failed product; some molecules “definitely leak out of us.” But the stonewall on anything client- or molecule-specific is absolute, and they refuse every point forecast — FY27 segment growth, debt quantum, quarterly anything — hiding, fairly enough, behind the genuine lumpiness of the business.

On delivery, the record so far is good. The 28–30% margin was promised as a two-to-three-year goal and arrived in FY26. The promised interest-cost decline showed up on schedule (₹78 crores to ₹39 crores, after IPO proceeds cut borrowings from ₹928 to ₹288 crores). Capacity timelines have held in broad shape with mild slippage at the edges — the second 225 KL reactor block drifted from “by Q4 FY27” to “FY28” between the February and May calls. Two quality-of-earnings items are worth keeping in the back pocket: some revenue is recognised on completion rather than dispatch (mix undisclosed), and Q3 FY26 included a ₹16 crore reversal of an earlier provision. Neither is damning; both reward watching.

Where It’s Going

The next two years are a capacity story. Reactor capacity goes from roughly 700 KL to 1,150 KL — about 70% more manufacturing muscle — in two tranches landing in FY27 and FY28, alongside a doubling of process R&D, 200 new discovery fume hoods, and a fresh greenfield site starting late FY27. Around a quarter of the new capex goes to capability rather than capacity: peptide development and pilot scale by September 2026, OEB labs for antibody-drug conjugates by October 2026, an oligonucleotide product already in commercial validation, and an animal-health unit (working with 3 of the top 5 players) targeting FY28 commercialisation. New modalities are still only ~4% of revenue — management’s “fast follower” posture means they build alongside customer demand rather than ahead of the science.

The demand backdrop they describe is large pharma consolidating full-lifecycle outsourcing into fewer Indian partners — “similar to trends witnessed in China” a decade ago — with the big China-to-India tech-transfer tranche having landed in 2023–24 and steady second-sourcing since. Biotech funding is recovering (up 52% year-to-date per the May call) but Kanumuri expects no meaningful new biotech formation for 18–24 months, so pharma carries the growth.

The tensions are real. Free cash flow is still negative (−₹83 crores in FY26) because capex eats everything operations generate, and the FY27 programme is twice the size — funded by accruals plus fresh debt onto a balance sheet that was scrubbed clean barely a year ago. Margins face input-cost inflation, logistics drag, and the inefficiency of ramping new plants, with cost recovery from open-book pharma pricing arriving late. The June quarter is a recurring air pocket (June 2024 was an outright loss), a reminder of how operationally geared the model is. And utilisation discipline matters: management’s own 2022–23 history of margins sagging when capacity preceded demand is the precedent they are betting against, this time with — they say — better visibility.

The Four Checks

1. Quality and moat. A good business with a real but partial moat. The moat is switching costs and trust: regulatory qualification across all three stages of a client’s lifecycle, 15–20-year relationships, and a clean compliance record (35 customer audits, zero critical observations in the trailing year). It is not impregnable — molecules leak to other suppliers, nothing is contractually guaranteed, and Chinese rivals remain bigger and more capable. Call it a strengthening moat in a structurally favoured niche, not a fortress.

2. Returns on incremental capital and runway. The trajectory is the argument: ROCE went 3% → 6% → 11% → 14% → 20% across FY22–FY26 as the last capex cycle filled up. Recent incremental capital is clearly earning well; the question is whether the next ₹1,100–1,300 crores repeats the trick. Management itself flags an asset-turn dip before recovery to 1.2–1.4x. The runway — large pharma’s India build-out — looks long and open; even management says it’s in “early stages.” Verdict: good and improving returns, with a deliberate two-to-three-year digestion period ahead.

3. Capital allocation for the stage. Rational. IPO proceeds went straight to killing debt (₹7.1 billion → ₹1.3 billion in one year), every rupee of operating cash goes into capacity while incremental returns run near 20%, and the zero dividend is the correct choice at this stage, whatever screener’s con-flag says. No buyback history to judge — at 10.5x book, none would make sense anyway. The one governance item to watch is soft: a founder-MD remuneration hike in year one of listing, with promoters holding only ~35%.

4. Price. Demanding, plainly. ₹26,042 crores of market cap is 73 times an FY26 profit that itself doubled, and 10.5 times book, with the stock 1% off its high. If management delivers its own conservative 15–20% growth at 28–30% margins, earnings roughly double again in three to four years — and the multiple still has to stay above 35–40x for a buyer today to do well. The price pays in advance for the capex cycle working and leaves little room for a June-quarter stumble, a margin digestion phase, or any wobble in the China+1 narrative. The business is performing; the valuation assumes it keeps performing without interruption.

Sources

• Earnings call transcripts: Aug 2025 (Q1 FY26), Nov 2025 (Q2 FY26), Feb 2026 (Q3 FY26), May 2026 (Q4 FY26/full year) — all from sailife.com via screener.in.
• Annual report: FY25 (first AR as a listed company; the extract was thin — MD&A body and proceeds-utilisation table didn’t parse, so FY25 detail leans on the balance-sheet notes and concalls). Only one AR exists post-listing, so the usual three-year AR read wasn’t possible.
• Screener.in consolidated snapshot, fetched 2026-06-10 (public, logged-out).
• Research dumps in vault/Sources/Earnings/Sai Life Sciences Ltd/ (not published).